A mesoporous silica nanoparticle includes a plurality of pores, a bioactive agent disposed in at least a portion of the ores, and an immunomodulatory moiety either disposed in a portion of the pores or bound to at least a portion of the outer surface of the nanoparticle.

The present invention relates to a double-stranded oligonucleotide which can highly specifically and efficiently inhibit an amphiregulin expression and, preferably, a double-stranded oligonucleotide comprising a sequence in the form of RNA/RNA, DNA/DNA or DNA/RNA hybrid, a double-stranded oligonucleotide structure comprising the double-stranded oligonucleotide, nanoparticles comprising the double-stranded oligonucleotide structure, and a fibrosis or respiratory disease preventive or therapeutic use thereof.

The present invention relates to a pharmaceutical composition comprising an amorphous adsorbate of lenalidomide, or a pharmaceutically acceptable salt thereof, on a porous carrier and one or more pharmaceutically acceptable excipients. The invention further relates to the use of said composition as a medicament, particularly in the treatment of multiple myeloma and myelodysplastic syndromes.

Provided herein are compositions and methods for diagnosis and treatment of early-stage atherosclerotic plaques and reduction of plaques in arteries. In particular, provided herein are high-density-lipoprotein-functionalized magnetic nanostructures (HDL-MNS) capable of (i) precise anatomic detection of atherosclerotic lesions, (ii) removal of excess cholesterol from macrophage cells in atherosclerotic plaque, and/or (iii) delivery of therapeutic agents to plaque locations, and methods of diagnosis and treatment of atherosclerosis.

A method of preparing iron oxide nanoparticles using an herbal mixture comprising Capparis spinosa, Cichorium intybus, Solanum nigrum, Cassia occidentalis, Terminalia arjuna, Achillea millefolium, and Tamarix gallica. The method produces crystalline γ-Fe.sub.2O.sub.3 nanoparticles which are superparamagnetic. The iron oxide nanoparticles are used in a method of killing or inhibiting the growth of a bacteria and/or fungus, particularly in the form of a biofilm. The nanoparticles are also used in a method of treating colon cancer.

A drug and layered silicate composite is provided. The drug and layered silicate contains layered silicate powders and a drug compound bound to between layers of the silicate powders, wherein the drug compound is present in an amorphous state in the composite. Using such a composite may significantly improve absorption and bioavailability of a sorafenib compound.

A method of treating, reducing or preventing bacterial infection in a wound, the method comprising: applying a film on the wound, the film including a biodegradable polymer with bacteriophages dispersed therein, wherein the polymer is a poly (ester amide urea).

Compositions and methods for prophylactically sustaining and/or maintaining a robust endocannabinoid system in patients for modulating excess inflammatory response and inflammatory diseases over the mammalian lifespan to mitigate age-related discomfort. Specifically, a method of treating inflammatory and neuropathic pain in a mammal by administering a synergistic pharmaceutical daily dosage form comprising: palmitoylethanolamide (PEA), beta-caryophyllene (BCP) and docosahexaenoic acid (DHA).

An immuno-therapy for treatment of a tumor is provided. An effective dose of a composition containing a low dose of superparamagnetic iron oxide nanoparticle is administered to a tumor. Once the composition has been administered, it is recommended to avoid any means that would cause direct cytotoxic effects to the cancer cells and to normal/healthy tissue. The combination of composition-administered cancer cells with the avoidance of direct cytotoxic effects has been shown to be successful to inhibit the growth of the cancer cells or result in aptosis of the cancer cells. Additional dose(s) can be administered when it is determined that: (i) the tumor starts to grow and/or (ii) the remaining composition falls below a threshold. The immuno-therapy method is a safe, clinically applicable, ready-to-use theranostic approach for cancer patients who are unable to start chemoradiotherapy in a timely manner, i.e. an effective interim or adjunctive treatment for patients.

Provided is a pharmaceutical composition containing pemafibrate, a salt thereof or a solvate thereof and having excellent homogeneity. The pharmaceutical composition is provided to contain the following components (A) and (B): (A) pemafibrate, a salt thereof or a solvate thereof; and (B) one or more selected from the group consisting of the following components (B-1) to (B-6): (B-1) a cellulose ether species; (B-2) a starch species; (B-3) a povidone species; (B-4) a silicic acid compound; (B-5) a polyhydric alcohol; and (B-6) an alkyl sulfate ester.